CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...
Phase 2
Scottsdale, Arizona, United States and 46 other locations
efficacy with the combination of a next generation anti-CTLA-4 antibody, ONC-392, and anti-PD-1 antibody, pembrolizumab, in platinum resistant ovarian...
Phase 2
Phoenix, Arizona, United States and 20 other locations
Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....
Phase 3
Phoenix, Arizona, United States and 176 other locations
phase the preliminary efficacy in subjects with ARID1a mutated ovarian clear cell and ovarian endometrioid cancers will be...
Phase 1
Phoenix, Arizona, United States and 22 other locations
of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...
Phase 3
Phoenix, Arizona, United States and 113 other locations
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (I...
Phase 3
Phoenix, Arizona, United States and 63 other locations
This is a Phase 2, open-label, randomized, 3-arm study to evaluate progression-free survival (PFS) in patients with recurrent platinum-resistant ovarian...
Phase 2
Scottsdale, Arizona, United States and 20 other locations
outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian...
Phase 2
Scottsdale, Arizona, United States and 22 other locations
, which are pieces of a protein known as "folate receptor alpha" (FRalpha), a protein that is found in high levels on ovarian cancer...
Phase 1, Phase 2
Scottsdale, Arizona, United States and 2 other locations
Ovarian cancer is a heterogeneous disease, characterized by complex molecular and genetic changes. The high expression of vascular ...
Phase 3
Phoenix, Arizona, United States and 202 other locations
Clinical trials
Research sites
Resources
Legal